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Abstract  
In Europe, neuropsychiatric diseases currently make up around one third of the total 
burden of disease. In 2004, 27% of the overall population was affected by at least 
one of the most frequent neuropsychiatric diseases such as Alzheimer dementia, 
Parkinson’s disease, stroke or depression. The annual costs of care exceed those of 
cancer, cardiovascular conditions and diabetes. In order to delay onset or course of 
neurodegenerative diseases, the available potential should be utilized. As well as 
improving quality of life of patients and relatives, this may reduce the great financial 
burden caused by neurodegenerative disorders. However, the availability of 
established drugs or therapeutic agents is very limited. This paper reviews the state 
of current knowledge on to what extend homocysteine metabolism is relevant for 
neurodegenerative and other neuropsychiatric diseases with particular emphasis on 
the evidence for prophylactic and therapeutic strategies.  
In the European countries, many people do not take the recommended daily 
minimum amount of folate and vitamin B12. Deficiency of these vitamins and 
secondary changes in the concentrations of associated metabolites, such as 
methylmalonic acid and homocysteine, may contribute to onset and progression of 
neuropsychiatric diseases. This paper reviews the evidence on whether substitution 
of folate and vitamin B12 is beneficial e.g. in several cases of cerebrovascular 
disease, dementia and depression.  
 
Introduction 
Worldwide, around 400 million people suffer from neurological and mental disorders 
[1]. The general consensus is that neuropsychiatric diseases make up around 35% 
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of the total burden of disease in Europe [2,3]. For example, in Europe, around 1.1 
million new cases of cerebral ischaemia are reported every year [4]. The annual 
treatment costs for a total of 127 million Europeans suffering from at least one of the 
most frequent neuropsychiatric diseases amounted to €386 billion in 2004, which is 
more than the costs caused by cancer, cardiovascular disorders or diabetes [2]. 
Apart from those direct costs for hospitalisation, medical and nursing care, 
rehabilitation, drugs, psycho- and physiotherapy, laboratory costs and medical-
technical services, there are additional indirect costs due to incapacity, disability and 
early death. 
In European countries, many people do not take the recommended daily minimum 
amount of vitamin B12 and folate (naturally occurring biologically active form of the 
vitamin) or folic acid (precursor of folate, e.g. ingredient of synthetic vitamin drugs) 
[5-7]. Deficiency of these vitamins and consecutive changes in the concentration of 
associated metabolites such as methylmalonic acid (MMA) and homocysteine may 
contribute to the onset and progression of neuropsychiatric diseases [8-15]. 
 
 
1. Metabolism  18 
1.1 Biochemistry 
 
Folate and vitamin B12 play an important role in the development, differentiation and 
function of the central nervous system. Both vitamins are involved in methionine-
homocysteine metabolism (figure 1). Methionine becomes activated to S-
adenosylmethionine (SAM), which is indispensable for numerous reactions involving 
methylation, e.g. in the synthesis of nucleic acids [DNA, RNA], proteins, 
neurotransmitters, hormones, fatty acids, polysaccharides, phospholipids or DNA 
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methylation [16]. For example, several neuroendocrinologically important micro-
molecules, such as noradrenaline and N-acetylserotonine, are converted by SAM 
dependent methylation reactions into biologically active neurotransmitters [17]. 
Others, such as L-DOPA, can be deactivated through SAM-dependent methylations. 
S-adenosylhomocysteine (SAH) results from SAM through the release of the methyl 
group. Due to antagonism, elevated SAH concentrations reduce the SAM-dependent 
methylation capacity and, by doing so, impair numerous metabolic processes in the 
brain [18]. Several cell dysfunctions, DNA damage and disturbed biosynthesis of 
myelin are potential consequences [19]. SAH is hydrolyzed into homocysteine. The 
reaction converting SAH into homocysteine is reversible and is favoured, when an 
increase in homocysteine levels occurs. Plasma homocysteine correlates closely 
with the SAH level in the cerebrospinal fluid and the brain in animals [20].  
Homocysteine is a neuro- and vasculotoxic sulphur-containing intermediary product. 
Homocysteine can be transsulfurated to cystathionine and, subsequently, to 
cysteine, which is a component of glutathione. Transsulfuration of homocysteine 
depends on vitamin B6. Alternatively, homocysteine can be remethylated to 
methionine by addition of a methyl group from 5-methyltetrahydrofolate (5-MTHF), 
which is synthesized by 5,10-methylenetetrahydrofolate reductase (MTHFR). 
Remethylation can be catalyzed by methionine-synthase (MS), which requires 
vitamin B12 in the form of methylcobalamin as cofactor. By the remethylation 
reaction of homocysteine to methionine, 5-MTHF is regenerated to 5,10-MTHF, 
which is necessary for nucleic acid synthesis. Thus, vitamin B12 deficiency leading 
to a reduced methylation rate of homocysteine to methionine can lead to a functional 
deficiency of 5,10-MTHF and subsequent dysfunction e.g. of the haematopoietic 
system (“folate trap”). Reduced remethylation of homocysteine to methionine and 
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SAM due to a lack of vitamin B12 or folate can yield elevated levels of homocysteine. 
Reduced synthesis of SAM can lead to a state of “hypomethylation” e.g. resulting in 
disturbed synthesis of neurotransmitters and proteins important for the structural 
integrity of the brain (figure 1) [21,22].  
 
The homocysteine metabolism in the brain is different from the systemic 
homocysteine metabolism. In the liver and the kidneys, there is an alternative 
pathway available for remethylation, apart from MS, the enzyme betaine-
homocysteine-methyltransferase (BHMT), but this enzyme has not been detected in 
the brain [23]. Alternatively, in other organs such as liver, kidney and the 
gastrointestinal tract, homocysteine can be irreversibly broken down into cysteine 
and glutathione via cystathionine through condensation with serine (transsulfuration). 
The activities of the two involved enzymes cystathionine--synthase (CBS) and -
cystathionase are each dependent on vitamin B6 as a cofactor. Similar to endothelial 
cells, neurons and other CNS cells do not seem to strongly express the complete 
homocysteine transsulfuration pathway, i.e., the activity of -cystathionase is low, 
although some brain transsulfuration activity has been reported, recently [24,25]. 
Hence, the capacity of homocysteine metabolism in the CNS is largely dependent on 
sufficient supplies of folate and vitamin B12 [26]. In particular, glia cells only have 
very small vitamin B12 stores that are quickly exhausted in cases of negative 
balance [27]. 
 
Due to the cofactor function of adenosylcobalamin for the mitochondrial 
methylmalonyl-CoA-mutase, vitamin B12 deficiency leads to the conversion of 
methylmalonyl-CoA to methylmalonic acid, which can be neurotoxic [8,28]. Another 
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CNS-specific feature is the dependence on the transport of folates through the 
blood-brain barrier. During this active transport process, 5-MTHF at the choroid 
plexus binds to folate receptor proteins and reaches the neurons through 
endocytosis, storage and release via the cerebrospinal fluid compartment [29,30]. If 
active folate transport or metabolism at the choroid plexus is disturbed, 5-MTHF 
levels can become low in the cerebrospinal fluid even in the presence of normal 
plasma folate concentrations [31]. By active transport, 5-MTHF occurs in higher 
concentrations in the cerebrospinal fluid [around 14-18 ng/mL] than in the blood [3-
12 ng/mL] [32]. Similarly, there exist active transport mechanisms for vitamin B6 and 
B12 [33,34]. 
 
1.2 Genetics 
In addition to the availability of vitamins, genetic variants contribute to the inter-
individual differences in homocysteine metabolism [35,36]. Several of these variants 
have been reported to be associated with neuropsychiatric diseases. However, 
literature is conflicting, and numerous studies did not observe any association of 
genetic variants of homocysteine metabolism with disease. The frequent missense 
variant of methylenetetrahydrofolate reductase (MTHFR) c.677C>T is (A222V) is 
associated with reduced enzyme activity, and homozygous carriers of this variant 
have a mean increase of plasma homocysteine levels of approximately 25%, 
whereas the effect on homocysteine levels is generally stronger when folate plasma 
levels are low [37-42]. Despite the association between MTHFR c.677TT and 
elevated homocysteine plasma levels, the association of this variant with different 
neuropsychiatric diseases is inconsistently reported in numerous studies [43-45]. 
Because homocysteine levels are modulated by factors like age, gender, smoking 
 
 
7
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
and renal function, the homocysteine increasing effect of MTHFR c.677C>T might be 
overridden or confounded by such factors [46-49]. Nevertheless, large meta-
analyses have proven that the T-allele is associated with cardio- and 
cerebrovascular disease, and this polymorphism may also be associated with the 
incidence of dementia [50-53].    
 
A lot of further studies investigated the association of other genetic variants of 
homocysteine metabolism with neuropsychiatric diseases. Although also negative 
results have been reported, there, e.g., may be associations between the variants 
CBS c.844_845ins68bp (p.-), MTHFR c.1298A>C (E429A), MS c.2756A>G 
(D919G), Tc2 c.776C>G (p.R259R),  with plasma homocysteine levels, birth defects, 
cerebrovascular disease, neurodegeneration, (neuro)oncological and psychiatric 
disorders [54-64]. In the opinion of the authors, none of the genetic variants of 
homocysteine metabolism has yet been proven to be of sufficient relevance for an 
individual to justify analysis in the clinical routine beyond studies. Data on the clinical 
relevance in terms of consequences for therapy or (secondary) prevention of 
neuropsychiatric diseases may be achieved in the next years.  
 
2. Vitamin deficiency in children, adults, and the elderly 
 
2.1. Children 
There is a need for a considerable amount of one-carbon groups for brain 
proliferation, cerebral maturation and myelination, particularly in newborns, children 
and adolescents during their growth period. Thus, disturbances of folate, vitamin B12 
and homocysteine metabolism can lead to psychomotor retardation and to a variety 
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of unspecific neuropsychiatric symptoms [31,32,65-67]. Dysfunctional homocysteine 
metabolism caused by genetic deficiencies leads to greatly elevated homocysteine 
concentrations in the plasma (>100 µmol/L), often presenting with neuropsychiatric 
disorders [67-69]. Examples are CBS deficiency [68,69], disturbances of intracellular 
cobalamin metabolism (cbIC, cblD, cblF, cbIE-, cbIG-defect) and MTHFR deficiency 
[67]. These rare congenital metabolism disorders need to be dealt with by a 
specialist department and are not the subject of the present review.  
However, also nutritional conditions can lead to severe disturbances of folate, 
vitamin B12 and homocysteine metabolism in children. In particular, babies breastfed 
by mothers with vitamin B12 deficiency, e.g., due to vegan diet, can be affected by 
serious and irreversible CNS damage [70,71].  
 
2.2. Adults 
In adults, folate or vitamin B12 deficiency mostly develop for months and years, 
before e.g. disturbed DNA synthesis and disturbed methylation lead to symptoms of 
(megaloblastic) anemia and neurological impairment such as forgetfulness, 
sleeplessness, tiredness, irritability, lethargy and mood swings [72]. Further 
progression may involve cerebral demyelinisation, seizures, impairment of the 
peripheral nervous system like hypo- or paraesthesiae, pareses, depression and 
dementia [73-75]. Importantly, up to 30% of patients with vitamin B12 deficiency and 
normal folate levels exclusively show neurological symptoms [75]. In particular, 
diagnostic attention must be paid to risk groups of folate and vitamin B12 deficiency 
such as pregnant women, patients with inflammatory gastric conditions, people 
taking relevant drugs and alcoholics [76].   
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Vitamin B6 acts as a cofactor in more than 100 enzymatic reactions and is involved 
in the synthesis of various neurotransmitters [77] such as those occurring in the 
tryptophan-serotonin metabolism. Vitamin B6 deficiency was suggested to be 
associated with migraine, chronic pain, seizures and depression [78] as well as 
cardio-vascular diseases [79], but according to our knowledge there is currently no 
robust data supporting the idea that vitamin B6 deficiency is epidemiologically 
relevant for neuropsychiatric diseases in Western European Countries. 
 
2.3 Elderly population 
The prevalence of vitamin B12 and folate deficiency increases with age and is 
common in the elderly [47,80]. Whilst serum and CSF concentrations of folate and 
vitamin B12 fall, those of homocysteine rise with age [81]. The cause of vitamin 
deficiency in higher age has been variously ascribed to chronic illnesses, side effects 
of medications, malabsorption, increased demand and poor diet [82]. In elderly 
Europeans, the average intake of folate is clearly below the recommended daily 
dose of 400 μg/day [83].  
Many neuropsychiatric diseases connected with the homocysteine metabolism, such 
as cognitive impairment, dementia, Parkinson’s disease and polyneuropathy, have 
their highest prevalence in elderly persons. Therefore, disturbances of homocysteine 
metabolism that are associated with neuropsychiatric diseases may be of 
pronounced importance for the elderly.  
 
3. Neuropsychiatric diseases 
The pathophysiological mechanisms of neuropsychiatric diseases can be divided 
into disease-specific and disease-non-specific damage. Interactions between 
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mechanisms of neuropsychiatric diseases with folate, vitamin B12 and 
homocysteine, which have been suggested in the literature, are summarised in table 
1. 
  
3.1. Cerebral ischaemia 
There is evidence that elevated plasma levels of homocysteine can affect the 
endothelium, promote growth of (vessel) smooth muscle cells and activate 
haemostasis [84] (see figure 2). Elevated plasma homocysteine is a confirmed risk 
factor for atherosclerotic diseases and thromboembolic events [76]. Meta-analyses 
have proven the association of elevated homocysteine levels with the risk of cerebral 
ischaemia [53,85,86]. The data collected in 30 retro- and prospective studies showed 
that a homocysteine difference of -3 µmol/L (~25%) is associated with an 
approximate 19-24% lower risk of cerebral ischaemia [53,87]. An exponential 
increase of risk for cerebral ischaemia was shown prospectively for lower dietary 
folate intake as well as for increased homocysteine levels [88,89]. Each µmol/L of 
homocysteine led to a risk increase of around 6-7% [90] with a 5 µmol/L rise in 
homocysteine levels raising the risk by 65% [87].  
Further, the resulting potential to lower the risk of developing ischaemia by 
approximately 19% [53,87] was confirmed in randomised controlled therapy studies 
involving high-risk populations. Although results of the first intervention studies have 
been regarded as disappointing at first, the Vitamin Intervention for Stroke 
Prevention (VISP) study based on 3680 probands in whom cerebral ischaemia had 
occurred, the relative risk of having another ischaemia event was lowered by 21% 
after 2 years of therapy with 2.5mg folic acid and other B vitamins daily [91]. 
Substitution of 2.5mg folate/ day together with vitamin B6 and B12 lowered the 
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relative risk of stroke by 24% during 5 years in the Heart Outcomes Prevention 
Evaluation (HOPE)-2 study involving 5222 patients with vascular disease or diabetes 
[92,93]. However, within the NORVIT study, a daily dose of a lower dose of folic acid, 
i.e., 0.8mg per day, did not proof to be effective in preventing stroke in patients with 
myocardial infarction [94]. 
 
According to a meta-analysis including 16,841 participants from eight randomised 
studies, folic acid therapy lowered the relative risk of suffering cerebral ischaemia by 
18% in all participants [86]. The effect correlated with the observed decrease of 
homocysteine levels. Importantly, analysis of subgroups showed that the effect of 
folate on the risk of cerebral ischemia was significant only for participants treated 
and followed-up for at least 36 months, whereas there was no significant effect in 
shorter treatment regimens indicating that intervention should be permanent and 
intervention studies should exceed duration of 36 months.  
Food fortification with folic acid in the US and Canada was shown to be associated 
with a significant drop in the number of deaths by cerebral ischaemia [95].  
In summary, folate supplementation has been proven to be effective in primary and 
secondary prevention of cerebral ischemia. Whether the effect of folate on 
homocysteine levels or other folate-dependent effects are the underlying 
mechanisms, remains unknown. The results of further, currently ongoing intervention 
studies may provide additional information in the near future [96,97]. 
 
 In conclusion, there is evidence that long-term supplementation of folate is 
effective in secondary stroke prevention (all patients) as well as for primary stroke 
prevention in patients at risk such as patients with diabetes mellitus or after 
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myocardial infarction. The best dose or combination with other B-vitamins, if any, has 
not been evaluated yet, but a daily dose of 2.5mg folic acid was shown to be 
effective in the HOPE2 and the VISP study [evidence category IA]. 
 
 
3.2. Impairment of cognitive functions 
 
Alzheimer’s Dementia (AD) is the most frequent form of dementia followed by 
vascular and mixed (Alzheimer and vascular) dementia [98]. If AD onset could be 
delayed five years, the number of people affected would approximately halve [99]. 
Folate, vitamin B12 and homocysteine metabolism may have impact on both AD and 
vascular dementia. Similar to the association of elevated homocysteine levels with 
major stroke, elevated homocysteine levels are associated with cerebral 
microangiopathy and microvascular brain lesions as biological correlate of vascular 
dementia [100-102]. However, there are putative biological mechanisms for the 
association of homocysteine with dementia exceeding cerebrovascular disease. First 
of all, homocysteine has neurotoxic effects in cell culture and in animal experiments 
[9,103]. Possible mechanisms of neurotoxicity of homocysteine are multiple and 
include activation of NMDA receptors, DNA damage [104], and binding of copper 
and concomitant cytochrome C oxidase deficieny [105]. Therefore, the presence of 
elevated homocysteine brain levels may well promote neuronal cell death during 
neurodegenerative processes.  
The AD brain is characterised by extracellular beta-amyloid (A) deposition and 
intracellular neurofibrillary tangles. Homocysteine metabolism influences the 
progression of these two histological hallmarks of Alzheimer disease in experimental 
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models. The amount of A production depends on expression of the amyloid 
precursor protein (APP) and different secretases splitting APP in an amyloidogenic 
or none amyloidogenic manner [106]. One of the most important mechanisms 
causing alteration of gene expression is disturbed DNA methylation. DNA 
methylation in general is accomplished through the specific enzymes, the DNA 
methyltransferases, which transfer a methyl group to the cytosine of CpG 
dinucleotides, and the degree of promoter gene CpG methylation is an important 
factor in gene silencing [107]. Due to the role of SAM as the ubiquitous methyl group 
donor and SAH as a strong inhibitor of SAM-dependent transmethylation reactions, 
lower levels of SAM and higher levels of SAH  result in a reduced methylation 
capacity in general and in reduced DNA methylation in particular [108,109]. It has 
previously been shown that low SAM levels are associated with decreased DNA-
demethylation followed by increased expression of presenilin 1 and β-secretase 
(amyloidogenic pathway), leading to an increase in Aβ production. Supplementation 
of SAM prevented these changes in cell culture experiments and mouse models 
[110-112] . 
In AD, neurofibrillary tangles are thought to result from hyperphosphorylation of tau 
protein. High concentrations of hyperphosphorylated tau protein (P-tau) predict the 
development of dementia [113]. Tau is dephosphorylated by protein phosphatase 2A 
(PP2A), and methylation of PP2A is required for correct binding and 
dephosphorylation of tau [114,115]. Incubation of Neuro-2a cells with SAH is 
associated with a decrease in PP2A methylation and associated with enhanced tau 
phosphorylation, and PP2s methylation becomes down-regulated in the brains of 
hyperhomocysteinemic mice [116]. 
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Thus, low plasma, CSF and brain levels of SAM and high levels of the 
methyltransferase-inhibitor SAH may promote both Aβ production and P-tau 
accumulation. In support of this hypothesis, SAM levels are decreased in brain tissue 
and cerebrospinal fluid of Alzheimer patients, [117,118] and increased SAH levels in 
brain tissues of Alzheimer patients correlate with disease progression and cognitive 
impairment [119]. Recent findings showed that oral substitution of SAM results in an 
increase in its plasma and CSF levels, and SAM substitution may lead to some 
clinical improvement in AD patients according to unconfirmed results [120]. 
 
Another link between homocysteine metabolism and neurodegenerative disorders in 
general and Alzheimer disease in particular is oxidative stress [121]. First of all, the 
brain is an organ with a limited baseline transsulfuration capacity, due to the limited 
activity of CBS and -cystathionase [122-124], which is crucial for the transsulfuration 
reaction of homocysteine to the glutathione component cysteine. Furthermore, the 
transsulfuration reaction is activated by SAM [125,126]. A lack of brain SAM may 
result in a reduced antioxidative capacity and increased oxidative stress (figure 1). 
 
Patients with dementia and reduced memory show lower levels of folate and vitamin 
B12 and higher levels of homocysteine in plasma and cerebrospinal fluid [127-134]. 
Homocysteine levels are associated with the severity of cognitive, physical and 
social impairments in demented patients [134-138]. Low folate or high homocysteine 
levels were reported to be associated with atrophy of the brain, in particular with the 
cortex, the amygdale and the hippocampi [139-144]. Otherwise apparently healthy 
people with folate or vitamin B12 deficiency are at elevated risk to develop cognitive 
impairment and dementia [131,143,145-151]. Differences in homocysteine plasma 
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levels were suggested to explain 5 to 16% of the variance of cognitive function of 
healthy individuals [149,152]. Elevated homocysteine levels were shown 
prospectively to be an independent risk factor for mild cognitive impairment (MCI) 
and its conversion into Alzheimer’s disease, and this association is dose-dependent 
[143,147-149,153-155]. The OR for the risk to develop dementia is increased by a 
factor of 2.8 to 4.6 in people with homocysteine levels of ≥14 µmol/L (compared with 
<10 µmol/L), and a 5 µmol rise in homocysteine levels is associated with a risk 
increase of approximately 40% [143,149,155]. Hence, a rise in homocysteine levels 
precedes the clinical onset of dementia, and persons with chronically elevated 
values have the highest risk of developing dementia. The available data cannot 
exclude that the rise of homocysteine levels in subjects developing dementia occurs 
after subclinical disease pathology onset. However, the association of low vitamin 
B12 and folate levels, which are associated with elevated homocysteine plasma 
levels, suggests that low folate, low vitamin B12 or homocysteine plasma levels are 
causally related with dementia.  
In prospective studies using imaging procedures, it has been proven that both in 
subjects suffering from dementia and in healthy individuals, low folate and increased 
homocysteine values are prospectively associated with decreased cortical and 
hippocampal volume and, in subjects with dementia, also with faster disease 
progression [139,142,143].  
 
An increased intake of folate or folic acid (diet or supplementation) was associated 
with a 50% lower risk of developing AD within 6 years [156]. Although literature is not 
univocal, some papers reported improved cognitive function in association with 
administration of folic acid or B vitamins. The largest study conducted so far involved 
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818 not demented, 50-70 years old participants with hyperhomocysteinemia, but 
normal vitamin B12 levels. The participants in the treatment group (0.8mg of folic 
acid over 3 years) performed significantly better in tests of sensomotoric speed, 
information processing speed and complex memory tasks) than those in the placebo 
group [157].   
 
There are some limitations concerning the transferation of these results to the clinical 
practise. The studies differed concerning population criteria, vitamin dose, treatment 
duration and specification of cognitive measurements. In regard of several negative 
results, further and long term studies are necessary to reconfirm previous positive 
study results and establish optimal protocols of folate and vitamin B12 intake [158].  
The possible protective effect of folate or vitamin B12 against dementia can be 
expected to be greater the earlier therapy is started, if homocysteine levels are 
elevated before treatment, and if the duration of therapy is sufficiently long 
[151,156,157,159,160].  
 
 
-> We conclude that there is evidence that low levels of folate and vitamin B12 and 
high levels of homocysteine are risk factors for mild cognitive impairment and 
dementia. In addition, they dispose towards an unfavourable clinical course. 
Supplementation of folate and vitamin B12 has beneficial effects for patients with 
mild cognitive impairment or Alzheimer´’s disease with evidence of category IIa. One 
may speculate that B vitamin supplementation might also be benefical in the 
maintance of cognitive function of healthy elderly individuals with high homocysteine 
levels. 
 
 
17
 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
3.3 Depression 
 
Depression is the most frequent psychiatric disease. It is underdiagnosed and 
undertreated, particularly in older patients [161]. Approximately one third of 
depressive patients show low levels of folate and elevated levels of homocysteine in 
serum or erythrocytes, and folate and SAM have been observed to be decreased in 
the cerebrospinal fluid [162,163]. Accordingly, neuropsychiatric disorders are 
frequent in patients with megaloblastic anaemia due to folate deficiency [164].  
In subjects with severe folate deficiency in the cerebrospinal fluid, greatly altered 
levels of monoamine metabolites such as hydroxyindole acetic acid and homovanillic 
acid have been found [165]. Folate also affects the synthesis rate of 
tetrahydrobiopterin (BH4), a cofactor for the hydroxylation of phenylalanine and 
tryptophan and is, therefore, directly involved in the synthesis of monoamine 
neurotransmitters [166]. Vitamin B6 (pyridoxal-5`-phosphate; PLP) acts as cofactor 
in the metabolism of tryptophan and serotonine, and a deficiency could be 
associated with depressive symptoms [78]. However, alternatively, depression may 
lead to altered nutritional behaviour as the reason for changed folate levels in 
depressive patients. However, the efficacy of a drug-based treatment using 
antidepressants seems to be influenced by initial folate values, as treatmentt is less 
effective in presence of folate deficiency (delayed or weaker effect) [167-170]. Pre-
treatment with folic acid [168] as well as the simultaneous administration of folic acid 
and fluoxetine leads to a significantly improved efficacy that correlates with changes 
in homocysteine levels [171], and low folate levels increase the risk of suffering a 
depressive relapse during fluoxetine therapy [172]. These associations were 
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stronger in women [173,174]. In a large sample of more than 5000 women 20-34 
years old Kendrick et al found folate levels to be associated with anxiety and 
depression, but adjustment for socioecomic and lifestyle factors weakend the 
association considerably. The authors concluded that socioeconomic factors are 
much more important for depression in their population of young female participants 
[175]. However, even in young individuals, this does not rule out a relevant role of 
folate in case of low folate levels [175] or when moderately decreased folate levels 
are combined with additional risk factors like the TT genotype of MTFR c.677C>T 
[176]. In addition to fluoxetin, folate levels also seem to influence the response to 
treatment with other antidepressants such as imipramine [167,168], nortriptyline and 
sertraline [168,177].  Folic acid and SAM may improve the efficacy of an 
antidepressant-based therapy through better availability of neurotransmitters and via 
further methylation reactions in the nervous system [178]. Folate and vitamin B12 
are necessary for SAM synthesis (figure 1). This relation may be a biological basis of 
the associations observed between folate and depression, as SAM is necessary for 
the synthesis of dopamine, noradrenaline, serotonine and 5-hydroxyindole-3-acetic 
acid in the brain [179,180]. Oral and intravenous SAM administration showed a 
mood-enhancing effect [181] and its antidepressant effect may be comparable with 
the classical tricyclical antidepressants [182]. However, currently, the clinical use of 
SAM itself for depression is not approved in most countries.  
 
Although several categories of antidepressants are available, approximately 30–40% 
of patients suffer from depression refractory to therapy [183].Therapy with folic acid 
should be taken into account as adjunctive treatment and may be beneficial even in 
cases with normal blood folate levels [184,185]. 
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 Concerning the majority of published results, folate deficiency favours depression 
and affects its duration and degree of clinical severity. Folic acid has antidepressant 
characteristics of its own and improves the therapeutic efficacy of antidepressant 
drugs. In cases of actual folate deficiency, folic acid administration can be 
particularly effective [evidence category IA]. In addition, SAM may have 
antidepressant effects (evidence category IIA). 
 
 
 
3.4. Parkinson’s Disease and L-DOPA Therapy 
 
Prospective studies in healthy subjects showed no connection between intake of 
folate and vitamin B12 and the risk of developing Parkinson’s disease [186], 
although one study reported an association of low levels of vitamin B6 and 
Parkinson´s disease [187]. The elevated homocysteine values observed in patients 
with Parkinson’s disease are due to L-DOPA therapy [188]. A large part of the 
administered L-DOPA receives methyl groups from SAM through the action of 
catechol-O-methyltransferase (COMT) being converted into 3-O-methyldopa. This 
reaction leads to a drop in SAM as well as an increase in SAH and homocysteine 
levels (the latter by 60–80%) [189-192]. Hence, administration of L-DOPA results in 
a rise in homocysteine values [193,194]. The group with the highest homocysteine 
concentrations also showed the highest concentrations of 3-OMT [194]. These 
changes in Parkinson patients can plausibly be reduced with COMT inhibitors [195]. 
Also in Parkinson patients, elevated homocysteine values in the plasma are 
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associated with a higher incidence of depression [189,196] and an increased risk of 
cardiovascular disease [188] and cerebral ischaemia [197,198]. The risk of 
Parkinson patients to develop dementia is four to six times higher [199] and is 
increased by the presence of hyperhomocysteinemia [196,200,201].  
 
 There is no evidence that disturbances of folate, vitamin B12 or homocysteine 
metabolism are relevant for the etiology of Parkinson´s disease. However, elevated 
homocysteine levels secondary to L-DOPA treatment in patients with Parkinson´s 
disease may accelerate neurodegeneration and may dispose to vascular disease 
and, thus, should be treated with folate and vitamin B12. In addition, vitamin B6 may 
be included in the supplementation regimen as it is necessary for homocysteine 
transsulfuration supporting the synthesis of glutathione. Glutathione is used for the 
defence against oxidative stress that is supposedly involved in neurodegeneration 
such as that seen in Parkinson’s disease [evidence category IIb]. 
 
 
3.5. Schizophrenia 
 
Compared with healthy individuals, patients with schizophrenia may have higher 
plasma homocysteine values [202], and elevated homocysteine or low folate levels 
seem to correlate with extrapyramidal motor symptoms induced by neuroleptic 
therapy and with negative symptoms of schizophrenia [203], although these results 
have not been sufficiently confirmed, yet. A meta-analysis of risk alleles for 
schizophrenia suggested that the T-allele of MTHFR c.677C>T, the most prevalent 
genetic disposition for elevated homocysteine plasma levels, may be associated with 
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schizophrenia [204]. However, the therapy studies published so far did not provide 
evidence that vitamin supplementation and homocysteine lowering had beneficial 
effects in the treatment of schizophrenia. A vitamin B6 supplementation was found to 
lower homocysteine levels, but there was no significant effect on schizophrenia 
symptoms [205]. A decrease in homocysteine levels in patients with initial values of > 
15 µmol/L has allegedly led to a significant improvement of clinical symptoms after 
three months in a small study [206].  
 
 
 The current data is insufficient to decide whether folate, vitamin B6, vitamin B12 
and homocysteine metabolism may be relevant for schizophrenia incidence, clinical 
course or treatment. [evidence category III]. 
 
3.6 Bipolar disorders 
 
Recent studies observed disturbances of homocysteine metabolism also bipolar 
disorders (BD). Ozebek et al. showed that homocysteine levels are higher, and folate 
levels are lower in patients with a bipolar disorder in comparison to healthy controls 
[207]. Additionally, the variants MTHFR c.1298A>C and MTR c.2756 A>G were 
shown to be associated with bipolar disorders [207,208]. Hyperhomocysteinemia 
may also play a role in the pathophysiology of neurocognitive deficits in BD, with a 
higher impact in older patients, or in patients, who had a delayed onset of illness 
[209-211]. Prospective studies are required to further analyse the role of 
homocysteine metabolism in the pathophysiology of bipolar disorders.  
 
 
 
22
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
 The current data is insufficient to decide whether folate, vitamin B6, vitamin B12 
or homocysteine metabolism may be relevant for bipolar disorder incidence, clinical 
course or treatment. [evidence category III]. 
 
 
3.7. Multiple Sclerosis  
 
A connection between vitamin B12 deficiency and multiple sclerosis (MS) has been 
suspected due to the fact that the illness is frequently accompanied by macrocytosis 
[212]. Irrespective of the course or stage of the disease, elevated concentrations of 
homocysteine have been found in the plasma and cerebrospinal fluid of MS patients 
[213,214] as well as lowered concentrations of vitamin B12 [215], whilst folate levels 
are normal [213]. As alternative to vitamin deficiency or at different stages of disease 
and treatment, elevated homocysteine levels in multiple sclerosis may also be the 
consequence of chronic inflammation processes or of cellular immune activation 
[213,216,217]. Prospective studies on vitamin concentrations in blood and the 
cerebrospinal fluid before disease onset are lacking. Based on experimental tests, 
there is a possibility that homocysteine metabolism plays a part in the creation or 
maintenance of the chronic inflammation process in MS patients. In the animal 
model of MS, an inhibition of transmethylation suppresses the CD4 cell-mediated 
autoimmune reactions [218]. 
 
Weekly vitamin B12 injections (i.m.) in 138 patients led to an improved clinical 
picture in the therapy group after 24 weeks whilst a combination therapy mixing 
vitamin B12 with lofepramine and L-phenylalanine did not produce an additional 
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therapeutic effect [219]. In a very small therapy group that received multivitamin 
preparation, the neurological findings were judged to have improved in comparison 
with the control subjects [220].  
 
 There is some evidence that folate, vitamin B12 and homocysteine metabolism is 
changed in patients with multiple sclerosis. Vitamin B12 and multivitamin substitution 
have been reported to be beneficial in single studies. However, the current data are 
insufficient to allow recommendations for diagnosis or treatment to be made 
[evidence category III]. 
 
3.8. Epilepsy and antiepileptic therapy 
 
Epileptic seizures are caused by the pathological stimulation or a lack of stimulation 
of nerve cells. NMDA receptors play an important part in the generation and 
maintenance of epileptic seizures. Homocysteine and other sulphur-containing 
metabolites (cysteine, homocysteine acid etc.) can trigger epileptic fits as agonists 
for NMDA receptors [221]. 
Several anticonvulsive drugs, even those of the newer generation, can interfere with 
folate metabolism [222]. Their intake lowers folate levels and is therefore associated 
with an increase in homocysteine concentrations [223]. Changes to plasma 
homocysteine levels have been observed above all during the application of 
phenobarbital, carbamazepine, primidone, phenytoin and valproate. Phenytoin and 
carbamazepine increase homocysteine by lowering folate and vitamin B6 levels 
[223,224]. Phenytoin, carbamazepine, phenobarbital and primidone induce the 
cytochrome (CYP) P450 enzyme system in the liver. Phenytoin is a substrate of CYP 
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2C9 as well as 2C19 and inhibits CYP 3A4, 5 and 7. Carbamazepine and 
phenobarbital induce CYP 2C19 or 2B6, whilst primidone is a substrate of CYP 2C19 
and does not have an inhibitory effect. In animal trials, phenytoin inhibits MTHFR 
activity [225]. Disturbed folate metabolism observed during the administration of 
antiepileptic drugs particularly during the first trimester could be one mechanism for 
the teratogenity of some anticonvulsive drugs [226]. In particular, carbamazepine 
and valproic acid were found to be associated with lowered serum folate levels as a 
possible risk of neural tube defects, but sufficient data on several antiepileptic drugs 
are missing [227,228]. This is why folic acid supplementation for women of 
childbearing age, who are on antiepileptics, is particularly indicated and is urgently 
recommended by the specialist societies [229,230].  
Further, elevated homocysteine and lowered folate concentrations can represent a 
risk factor for the occurrence of an interictal (occurring between seizures) psychosis 
[231]. Development of depressive symptoms has also been reported by patients on 
antiepileptic drugs [169,232]. In the animal model, adding folic acid supplements to 
anticonvulsive therapy has a mood-enhancing effect, improves cognitive functions 
and raises the seizure threshold [233].  
 
In children [234] and adults [235] on anticonvulsive drugs, the daily intake of 0.4 to 
1.0 mg of folic acid lowers elevated homocysteine values in most cases within 1-3 
months. The treatment of folate-deficient epileptics with 5 mg folic acid over 1–3 
years was reported to lead to improved initiative, attention, concentration, mood and 
social behaviour [236]. An adjuvant therapy with vitamin B6 lowered the severity of 
epileptic seizures even in those forms of paediatric epilepsy that do not belong to the 
congenital pyridoxine- and pyridoxal-5`-phosphate-dependent forms [77].  
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 Antiepileptic drugs can raise homocysteine concentrations supposedly due to 
their interaction with the folate metabolism. Since valid data are missing for several 
of the antiepileptic drugs, it is recommended that monitoring of folate and vitamin 
B12 levels should be performed in all patients treated with antiepileptic drugs in the 
long-term. In case of abnormal results and, concerning folate, in women of 
childbearing age, vitamins should be substituted [evidence category IIb and Ic-Ia for 
women of childbearing age].  
 
4. Safety of multivitamin therapy 
Multivitamin therapy may be not safe for everyone. Folate therapy can have negative 
effects in persons with subclinical vitamin B12 deficiency [237]. This should be 
avoided by excluding vitamin B12 deficiency before folate therapy, or by 
supplementing folate together with vitamin B12 in a dose of least 400µg per day. 
Folate is essential for nucleotide synthesis and DNA methylation. Therefore, folate 
deficiency has been associated with increased risks of several cancer types. 
However, high amounts of folate intake may also increase liability to cancer 
consistent with the role of folate in cell proliferation [238]. Although a safe upper limit 
of folic acid intake of 1 mg/d for adults and 300–800 g/d for children, depending on 
age, has been proposed there is no consensus about what blood concentrations of 
folate might cause harm, if any [239]. 
 
 
Expert commentary 
Elevated plasma homocysteine levels are a risk factor for stroke. Whereas, in the 
NORVIT study, daily substitution of 0.8mg folate did not prove to be effective in 
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secondary stroke prevention, 2.5mg folate significantly reduced the risk for 
secondary stroke in the HOPE2 and the VISP study. Accordingly, the meta-analysis 
of Wang and co-workers which included 8 intervention studies reported a significant 
preventive effect of folate supplementation against stroke. Most current guidelines, 
however, do not recommend vitamin substitution for homocysteine lowering in 
secondary stroke prevention, which supposedly means that some avoidable strokes 
are not prevented.  
Elevated levels of plasma and CSF homocysteine may promote diseases like mild 
cognitive impairment, Alzheimer’s disease and vascular dementia by several 
mechanisms. In addition, homocysteine as NMDA-receptor agonist may directly 
interfere with antidementive drugs like NMDA-receptor antagonists. In patients with 
cognitive deficits, folate, vitamin B12 and homocysteine should be determined, and 
abnormal levels should be treated. Substitution may be beneficial even in cases of 
values within the reference ranges.  
Although a lack of folate and vitamin B12 and elevated levels of homocysteine 
promote neurodegeneration, there is no evidence at the clinical level that folate, 
vitamin B12 and homocysteine metabolism is involved in the specific aetiology or 
pathogenesis of Parkinson’s disease. However, L-DOPA therapy leads to elevated 
homocysteine levels which may speculatively have adverse effects on Parkinson’s 
disease in addition to the general risks associated with elevated homocysteine 
levels. Thus, measurement of plasma levels of homocysteine is recommended in L-
DOPA treated patients, and elevated levels should be treated. Similarly, several 
antiepileptic drugs are associated with decreased levels of folate and increased 
levels of homocysteine, and they should also be treated. In addition, women of 
childbearing age treated with antiepileptic drugs should control folate and vitamin 
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B12 plasma levels and should, if levels are below the reference range, increase the 
folate prophylaxis for pregnancy to 2.5mg per day starting three months before 
possible conception in addition to supplementation of vitamin B12, e.g. 100µg per os 
per day, if necessary [240,241]. Women with instable epilepsy treated with phenytoin 
should consult a specialist prior to vitamin B12 substitution, as vitamin B12 
supplementation may reduce phenytoin efficacy according to this paper´s 
authors´experience.  
Depression is associated with low plasma levels of folate and high plasma levels of 
homocysteine. A reduced synthesis of SAM, which is related to such laboratory 
findings, may be an underlying mechanism of such associations, as SAM is 
necessary for neurotransmitter synthesis and may be relevant for the efficacy of 
several antidepressant drugs. We conclude that there is a case for determination of 
folate, vitamin B12 and homocysteine levels in patients suffering from depression, 
and abnormal levels should be treated. Even in patients with normal values, folate 
substitution may have antidepressant effects or may increase the effects of 
antidepressant drugs, especially in patients with otherwise drug-resistant depression. 
Thus, adjuvant treatment with folate is a considerable safe therapeutic option for 
several patients with depression.  
Concerning other neuropsychiatric diseases such as multiple sclerosis or 
schizophrenia, there is speculation, but no evidence, that folate, vitamin B12 and 
homocysteine metabolism may have any impact.  
Safety: Even after the prolonged use of high doses, the toxicity of folic acid remains 
low [242]. However, due to the risk of masking megaloblastic anaemia and 
irreversible neurological disorders, it is not recommended to carry out folic acid 
therapy without first excluding a causal vitamin B12 deficiency or co-supplementing 
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vitamin B12, in particular in elderly people [242]. In addition, folate supplementation 
is controversially discussed to promote tumour development or growth. Thus, 
therapeutic folate supplementation should be restricted to selected populations, until 
such issues have been solved. It is the opinion of the authors of this paper that folate 
supplementation is advisable for prevention of stroke in populations at risk, in 
patients with mild cognitive impairment or dementia and in selected patients suffering 
from depression in addition to persons with folate levels below the reference range 
and women who might become pregnant. Based on much therapeutic experience, 
vitamin B12 (cyanocobalamin and hydroxocobalamin) is considered to be well 
tolerated. Accordingly, the Food and Nutrition Board of the Institute of Medicine at 
the National Academy of Sciences has not issued an upper limit for vitamin B12 
intake. However, high doses exceeding 900µg per os per day may lead to vitamin-
B12-acne in rare cases in the experience of the authors.  
Vitamin B6 is regarded as safe within the dosage range of 2-25 mg in the experience 
of the authors, which should be sufficient for treatment of levels below the reference 
ranges [76]. At doses over-exceeding 25 mg, or the more, exceeding 50 mg, side 
effects like paraesthesia were frequently reported by the respective patients.  
Concerning laboratory analysis of the vitamins involved in homocysteine metabolism, 
the determination of the biologically available form of vitamin B12, 
holotranscobalamin, may be superior to the determination of total vitamin B12 [243]. 
However, this does not reflect the authors’ experience. In questionable cases, 
determination of methylmalonic acid may be much more informative. 
 
Five-year view 
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For decades, B-vitamins played an important role in the treatment of neurological 
diseases, and hyperhomocysteinemia has, for a long time, been seen as an 
important risk factor for cerebrovascular disease. Today, B-vitamins and 
homocysteine are often regarded as past topics that have lost their eligibility in the 
treatment and prevention of neuropsychiatric disease, which may in part be due to 
over-exaggerated expectations or lobbyism. There is evidence that folate, vitamin 
B12 and homocysteine metabolism can interact with the aetiology and pathology of 
neuropsychiatric diseases. Manipulation of this metabolism can be beneficial e.g. in 
relation to stroke prevention and improved clinical course of dementia or depression. 
Since simple therapies such as vitamin substitution may have clear positive effects 
on diseases as mentioned it is opportune to reconsider and change current 
guidelines basing on the evidence of large studies and meta-analyses published in 
high-ranked peer-reviewed. In five years, additional studies will have finished and, 
hopefully, we will be able to recommend more exact doses and protocols for 
treatment and prevention with folate and vitamin B12 for clearer defined populations.  
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Key issues (8-10 bullet points summarized in the review) 
 Folate substitution is effective in selected primary and in secondary 3 
prevention of stroke. A dose of 2.5mg per day per os has been proven to be 
effective, although lower doses may be effective, too. The combination with 
vitamin B12 may have additional benefitial effects and may improve the safety 
of folate supplementation. Low doses of 15µg vitamin B12 per day per os may 
be sufficient, but also higher doses like 100µg can be expected to be safe. 
The preventive effects increase when supplementation is long-term or 
continuous. Patients of countries with folate fortification or with low baseline 
homocysteine levels have lower benefit.  
 Folate, vitamin B12 and homocysteine levels should be determined in patients 
with dementia or depression and, repeatedly, e.g. once a year, in patients 
treated with antiepileptic drugs or with L-DOPA. Abnormal levels should be 
treated.  
 Folate itself exerts antidepressant effects in animal models and promotes the 
effects of other antidepressant drugs, in particularly in patients with otherwise 
drug resistant depression. Folate supplementation maybe considered in 
patients with depression.  
 Substitution of folate and vitamin B12 may improve cognitive functions even in 
the absence of folate or vitamin B12 deficiency. 
 The costs of treatment with folate and vitamin B12 should be covered by 
health insurance schemes for prevention of vascular events in patients at risk 
as well as for cognitive impairment, dementia and depression. Treatment 
guidelines should be modified.  
 
 
31
 The impact of folate, vitamin B12 and homocysteine metabolism on other 1 
common neuropsychiatric diseases including multiple sclerosis and 
schizophrenia has not been proven.  
2 
3 
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Evidence categories refer to therapeutic usefulness.  
 
Classification: 
 
Class I  Conditions with regard to which there is evidence and/or general agreement 
that the procedure or treatment is beneficial, useful, and effective. 
Class II  Conditions with regard to which there is conflicting evidence and/or a 
divergence of opinion about the usefulness/efficacy of a procedure or treatment. 
Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy. 
Class IIb Usefulness/efficacy is less well established by evidence/opinion. 
Class III  Conditions for which there is evidence and/or general agreement that the 
procedure/treatment is not useful/effective and in some cases may be harmful. 
 
Level of evidence A Data derived from multiple randomized clinical trials. 
Level of evidence B Data derived from a single randomized trial or non-randomized 
studies. 
Level of evidence C Only consensus opinion of experts, case studies, or standard-
of-care. 
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Figure 1. The Homocysteine Metabolism 
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Figure 2. Electron micrographs of cerebral arterioles in a CBS +/+ mouse fed control 
diet (left) and a CBS +/- mouse fed high-methionine diet (right). Vascular lumina (L) 
are oriented toward the bottom. Components of the vessel  wall include endothelium 
(asterisk), elastin (E), smooth muscle (SM), collagen (closed arrows), and basement 
membrane (open arrows). Bar = 1 µm. Reproduced from the article “Structure of 
Cerebral Arterioles in Cystathionine b-synthase deficient mice", Circ Res. 2002 Nov 
15;91(10):931-7. With kind permission of Gary Baumbach. 
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osmolysis 
 
Figure 3. Selected mechanisms of neurotoxicity of homocysteine. 
Homocysteine (HCYS) can enter the cell from the extracellular space, but also 
activate the NMDA receptor. This leads to intracellular increase of Ca2+ and 
accumulation of reactive oxygen species (ROS). In addition, homocysteine itself can 
increase intraneuronal concentrations of ROS. ROS, e.g., increase the intracellular 
activation of matrix metalloproteinases (MMPs), increase NFB and induce 
endoplasmatic reticulum stress and mitochondrial dysfunction, cell swelling and 
osmolysis of the cell. Homocysteine has inhibitory function at the GABA receptor 
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reducing NAPH oxidase activity and promoting oxidative stress. Furthermore, 
homocysteine forms toxic complexes with copper which can, e.g., induce DNA 
damage and can cause reduced activity of copper-dependent enzymes like the 
superoxide dismutase or the cytochrome C oxidase as part of the mitochondrial 
respiratory chain. Intracellular oxidative stress and interaction with expression, 
phosphorylation and activation of neuronal proteins are discussed as mechanisms of 
the association of elevated homocysteine levels with an increased formation of 
phospho-Tau and -Amyloid in Alzheimer’s disease. 
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 Hcy FA  B12 
Β- and -secretases (then Aß )    
Reactive (free) oxygen radicals    
Ca2+ concentration (cytosol)    
Glutamate excitotoxicity     
MPTP-induced neurotoxicity    
Iron-(copper-)induced neurotoxicity    
DEW-protein phosphorylation    
ATP concentration    
NMDA activation    
Amyloid ß-induced neurotoxicity, oxygen radicals, apoptosis    
ADMA    
NO bioavailability    
MPTP toxicity    
DNA strand breaks    
DNA repair    
Transmethylation    
S-Adenosylmethionine (SAM)  () () 
S-Adenosylhomocysteine (SAH)  () () 
Methyltransferase activities  () () 
Endoplasmic reticulum stress    
Cell cycle (Cyclin B and E)    
Endothelial damage    
Activity of Na+/K+-ATPase     
Hypomethylation    
COMT activity    
LDL oxidation, lipid peroxidation    
Inflammation, protease activation (MMP, TNF)     
Mitochondrial complex inhibition    
Synapse dysfunction, degeneration  ()  
Myelinisation    
Tetrahydrobiopterine synthesis     
Neurotransmitter synthesis    
Microangiopathy, ischaemia, hypoxy    
Presenilin ½ protein expression    
NTPDase* activity    
5`-Nucleotidase activity    
Respiratory chain complex I activity    
Protein kinase-C activity    
Methylation (e.g. DNA)    
Na+, K+-ATPase activity    
Protein phosphatase 2A    
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 Table 1. Metabolic conditions observed in association with increased homocysteine 
(Hcys), or decreased folic acid (FA) and vitamin B12 plasma levels 
Tyrosinhydroxylase activity    
NF-B activation    
mGluR activity    
Glutathione-oxidase activity    
HERP protein expression    
Leukoaraiosis    
GFAP mRNA expression    
EGF expression    
PARP activation    
Caspase activation    
 
NMDA = N-methyl-D-aspartate-receptor; NTPDase= nucleoside triphosphate 
diphosphohydrolase; COMT = catechol-O-methyltransferase, mGluR = group 1 
metabotropic glutamate receptors; ADMA = asymmetric dimethylarginine; NO = nitric 
oxide; HERP = homocysteine-inducable endoplasmic reticulum stress protein; MPTP 
= 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MMP = metalloproteinases, TNF = 
tumor necoris factor ; GFAP = glial fibrillary acidic protein; EGF = epidermal growth 
factor; PARP = poly-ADP-ribose-polymerase.  = reinforcement, stimulation,  = 
reduction, inhibition.  
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